Anthacycline-Induced Dendritic Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing dendritic cells from progenitor cells are time-consuming and costly, requiring lengthy culturing periods and large amounts of cytokines, which hampers their efficacy in immunotherapy applications.
Innovation Solution
Contacting CD34 positive cells with anthracyclines and/or anthracenediones accelerates their differentiation into functional dendritic cells within a shorter timeframe, reducing the need for cytokines and culturing time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cytokine-based methods are used to differentiate CD34 positive cells into dendritic cells, then functional dendritic cells are produced, but the process requires lengthy culturing periods and large amounts of cytokines
Solution Approach 1:
The patent changes the chemical parameters of the differentiation medium by replacing conventional cytokines (GM-CSF, TNF-α, IL-4) with anthracycline compounds (doxorubicin, daunorubicin, mitoxantrone) at specific concentrations (0.01-10 μM). This parameter substitution dramatically accelerates the differentiation process from weeks to days while maintaining dendritic cell functionality and morphology
Solution Approach 2:
The patent employs short-term exposure to anthracycline compounds (1-7 days) compared to conventional long-term cytokine treatment (2-4 weeks). The anthracyclines act as temporary inducers that kickstart differentiation, after which cells can be harvested without requiring prolonged maintenance in expensive cytokine-containing media
2Productivity
If conventional cytokine-based methods are used to differentiate CD34 positive cells into dendritic cells, then functional dendritic cells are produced, but the process is costly requiring large amounts of cytokines
Solution Approach 1:
The patent substitutes expensive cytokines (GM-CSF at 100-1000 ng/mL, TNF-α at 10-100 ng/mL, IL-4 at 10-100 ng/mL) with inexpensive anthracycline compounds (doxorubicin, daunorubicin, or mitoxantrone at 0.01-10 μM). This chemical substitution reduces the quantity of expensive biological reagents while maintaining differentiation efficiency
Solution Approach 2:
The patent uses low-cost anthracycline compounds that can be administered in small quantities for short durations (1-7 days), replacing the need for large volumes of expensive cytokines required for 2-4 weeks of conventional culture. The anthracyclines serve as potent, short-acting differentiation inducers
3Loss of time
If anthracyclines and/or anthracenediones are used to accelerate differentiation, then culturing time is reduced, but the mechanism of action differs from conventional cytokine pathways
Solution Approach 1:
The patent employs anthracycline compounds as intermediary substances that mediate the differentiation process by targeting topoisomerase II and inducing DNA damage responses, which subsequently activate differentiation pathways. This intermediary mechanism bypasses the need for complex cytokine signaling cascades while achieving rapid dendritic cell generation
Data Source
AI summary
The presentinvention relates to a method for the production of functional dendritic cells wherein CD34 positive cells are contacted with compounds inducing and accelerating the differentiation of these CD34 positive cells into functional dendritic cells. More in particular, the CD34 positive cells are contacted with anthracyclines and/or anthracenediones. In another aspect, the current invention relates to the cells obtainable by the method according to the invention. In a further aspect the current invention relates to the use of compounds such as anthracyclinesand/or anthracenediones that induce and accelerate the differentiation of CD34 positive cells into functional dendritic cells in the manufacture of a medicament for inducing an immune response in human in need thereof.